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ABSTRACT
Introduction: A step-up strategy for dipeptidyl peptidase (DPP)-4 inhibitor-based regi-
mens has not yet been established. In addition, similarities and differences between DPP-4
inhibitors and glucagon-like peptide (GLP)-1 receptor agonists remain to be elucidated in
humans. We investigated the pleiotropic effects of vildagliptin vs liraglutide in patients
with type 2 diabetes on sitagliptin-based regimens in an open-label, randomized, clinical
trial.
Materials and Methods: A total of 122 patients with type 2 diabetes that was
inadequately controlled by sitagliptin-based regimens were randomly assigned to either
vildagliptin (50 mg, twice daily) or liraglutide treatment (0.9 mg, once daily) for 12 weeks.
The primary outcomes were glycated hemoglobin and body mass index.
Results: Both vildagliptin and liraglutide significantly lowered glycated hemoglobin
within 12 weeks after switching from sitagliptin, but liraglutide produced a greater
reduction (-0.67 – 0.12% vs -0.36 – 0.53%). Liraglutide lowered body mass index, whereas
vildagliptin did not affect body mass index. Vildagliptin lowered fasting C-peptide immuno-
reactivity, but liraglutide did not. Vildagliptin increased serum levels of adiponectin, arachi-
donic acid, eicosapentaenoic acid and docosahexaenoic acid, whereas liraglutide had no
effect on these levels. Quality of life, assessed using the diabetes treatment satisfaction
questionnaire, was not impaired in either group. The most common adverse events were
gastrointestinal symptoms, which occurred with similar frequencies in both groups.
Conclusions: Vildagliptin-mediated improvements in glycemic control did not correlate
with indices for insulin secretion and insulin sensitivity. Switching from sitagliptin to
liraglutide is useful in managing hyperglycemia and weight. Each agent exerts unique
pleiotropic effects. This trial was registered with the University Hospital Medical Information
Network Clinical Trials Registry (no. 000004953).
INTRODUCTION
Recent large-scale clinical trials have suggested that intensive
antidiabetic therapies that cause unnecessary hyperinsulinemia
do not achieve satisfactory cardiovascular outcomes in people
with type 2 diabetes, possibly causing hypoglycemia and weight
gain1. One possible solution for this paradox came from the
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launch of incretin-based agents, because agents of this class
avoid unnecessary hyperinsulinemia, and thereby avoid hypo-
glycemia and weight gain. Incretin-based therapy consists of
two drug classes: dipeptidyl peptidase (DPP)-4 inhibitors, which
prevent enzymatic inactivation of endogenous glucagon-
like peptide (GLP)-1; and GLP-1 receptor agonists, which have
biological activity similar to GLP-1, but are resistant to DPP-42.
Incretin-related agents have generally been accepted as second-
or third-line therapy for ﬁrst-line metformin therapy3. Further-
more, incretin-based therapy is thought to be more effective for
type 2 diabetes in Asian people than in Caucasian people4. To
date, a step-up strategy from DPP-4 inhibitor-based regimens
has not yet established in Asian people with type 2 diabetes,
especially with the aim to avoid hypoglycemia and weight gain
as a result of unnecessary hyperinsulinemia. In this regard,
strong DPP-4 inhibitors or GLP-1 receptor agonists are the
candidates of choice. In a head-to-head comparison study,
liraglutide was superior to sitagliptin in reducing glycated
hemoglobin (HbA1c) and weight5. Beyond a class effect, which
DPP-4 inhibitor is most effective at lowering HbA1c remains
controversial6,7. However, greater reductions in HbA1c and fast-
ing plasma glucose level (FPG) were found with vildagliptin
compared with the other DPP-4 inhibitors in meta-analysis
and systematic review7. Based on these observations, we
hypothesized that vildagliptin and liraglutide are beneﬁcial in
managing hyperglycemia and weight when switched from sitag-
liptin. The present study was designed to compare the efﬁcacy
of vildagliptin and liraglutide in Japanese patients with type 2
diabetes who are inadequately controlled with sitagliptin-based
therapy. We also aimed to clarify the similarities, differences,
and pleiotropic effects of GLP-1 receptor agonists and DPP-4
inhibitors in the treatment of type 2 diabetes.
MATERIALS AND METHODS
Overview
This was a randomized parallel-group study carried out in
Japanese patients. It was designed in accordance with the prin-
ciples of the Declaration of Helsinki, and the protocol was
reviewed and approved by the institutional review board of
each study site. Patients provided written informed consent
before participation.
A total of 122 patients with type 2 diabetes who did not
achieve adequate glycemic control with sitagliptin-based regi-
mens (HbA1c >6.9%) were recruited at the Division of Endo-
crinology and Metabolism, Kanazawa University Hospital
between January 2011 and February 2012. Type 2 diabetes was
diagnosed according to World Health Organization criteria,
based on a 2-h plasma glucose value of >11.1 mmol/L8. This
trial was registered with the University Hospital Medical
Information Network Clinical Trials Registry (no. 000004953).
Patient Eligibility
Eligible participants were aged 20–80 years, had type 2 diabetes
mellitus, had moderately controlled diabetes with a change in
HbA1c of <3% within 12 weeks before screening and had been
treated with sitagliptin (50 mg, once daily) for 3 months or
longer. Exclusion criteria were as follows: (i) hypersensitivity or
contraindication to vildagliptin or liraglutide; (ii) history of type
1 diabetes or history of ketoacidosis; (iii) repeated episodes of
unexplained hypoglycemia, as deﬁned by a FPG <60 mg/dL,
with or without symptoms of hypoglycemia; (iv) concomitant
infection or planned surgery; (v) treatment with vildagliptin or
liraglutide within 12 weeks before screening; (vi) concomitant
corticosteroid therapy; (vii) poorly controlled diabetes (states of
hyperglycemic hyperosmolar syndrome and diabetic ketoacido-
sis); (viii) dialysis and serum creatinine >2.5 mg/dL in men or
>2.0 mg/dL in women; (ix) alanine aminotransferase (ALT)
and/or aspartate aminotransferase (AST) >2.5-fold above the
upper limit of the normal range; (x) poorly controlled hyper-
tension, systolic blood pressure >160 mmHg or diastolic blood
pressure >100 mmHg; (xi) current and/or previous heart fail-
ure; (xii) severe retinopathy; (xiii) malignancy on an active ther-
apeutic regimen or without complete remission or cure; (xiv)
pregnancy or breast-feeding; and (xv) inability to participate in
the study (psychiatric status or psychosocial status) as assessed
by the investigators.
Efﬁcacy End-Points
A computer-generated randomization sequence assigned partici-
pants in a 1:1 ratio to treatment with vildagliptin or liraglutide.
Dynamic randomization was used to adjust for demographic
differences (age, sex, prestudy antidiabetic treatment combined
with sitagliptin, and HbA1c) between the treatment groups. In
this active-comparator, parallel-group trial, eligible participants
switched from sitagliptin to vildagliptin or liraglutide, and
received each treatment for 12 weeks. Vildagliptin (Novartis
Pharma AG, Basel, Switzerland) was started and maintained at
100 mg daily (50 mg in the morning and 50 mg in the even-
ing). Liraglutide (Novo Nordisk, Bagsværd, Denmark), injected
subcutaneously with a pen device, was started at 0.3 mg/day,
and escalated by 0.3 mg/3 days to 0.9 mg/day (maximum
allowable dosage in Japan).
A total of 25 participants were required in each group to
achieve 83.8% of power to detect a difference of 0.51% in
HbA1c (standard deviation of 0.6% and a two-sample one-
sided alpha of 0.05), and 90.9% of power to detect a difference
of 1.9 kg in bodyweight (standard deviation of 2.0 and a two-
sample one-sided alpha of 0.05). With the assumption of a
50% dropout rate, we enrolled 122 patients (60 per arm).
The primary efﬁcacy end-point was the change from baseline
in HbA1c and body mass index (BMI) at week 12. Secondary
end-points recorded at baseline and week 12 were: fasting
plasma glucose; laboratory evaluations, including hematology,
serum chemistry, blood 1,5-anhydroglucitol (1,5-AG), fasting
serum insulin (IRI), C-peptide immunoreactivity (CPR), fasting
lipid proﬁle including small dense low-density lipoprotein
(sdLDL), adiponectin, tumor necrosis factor (TNF)-a, leptin;
urinary 8-hydroxy-deoxyguanosine (U-8OHdG) excretion;
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blood pressure; and physical measures (waist circumference and
bodyweight). Urinary albumin (U-Alb) levels were measured by
immunoturbidimetry and adjusted using urinary creatinine.
CPR index (CPI) was calculated as (100 9 fasting CPR [ng/
mL])/(18 9 FPG [mmol/L])9. The homeostasis model assess-
ment of insulin resistance (HOMA-IR)10 was used as a conven-
tional index for insulin resistance, and was calculated as
(fasting insulin [U/mL] 9 FPG [mmol/L])/22.5. Also, regarding
limitations of HOMA-IR when the FPG is above 140 mg/dL,
we additionally calculated a parameter of insulin sensitivity
quantitative insulin sensitivity check index (QUICKI), which
reﬂects insulin sensitivity even under hyperglycemic conditions.
QUICKI was calculated using the logarithmic transformation:
1/(log fasting insulin [U/mL] + log fasting glucose [mg/dL]).
To assess basic insulin secretion by b-cells, homeostasis model
assessment-b (HOMA-b) was calculated as fasting insu-
lin 9 20/(fasting glucose-63)10.
Serum fatty acid levels were measured as a secondary out-
come. A serum sample (approximately 0.2 mL) and 2 mL of
chloroform-methanol (2:1) was placed in a Pyrex centrifuge
tube, homogenized with a Polytron homogenizer (PCU-2-110;
KINEMATICA GmbH, Steinhofhale, Switzerland), and then
centrifuged at 80 g for 10 min. An aliquot of the chloroform-
methanol extract was transferred to another Pyrex tube and
dried under a stream of nitrogen gas. The dried sample was
dissolved in 100 lL of 0.4 mol/L potassium methoxide metha-
nol/14% boron triﬂuoride-methanol solution, and the fatty acid
concentrations were measured at SRL Inc. with a gas chromato-
graph (Shimizu GC 17A, Kyoto, Japan).
Treatment satisfaction was another secondary outcome, and
was assessed at baseline and at the end of the study using the
diabetes treatment satisfaction questionnaire (DTSQ)11–13. The
overall treatment satisfaction score was calculated as the sum of
DTSQ items 1 (Satisfaction), 4 (Convenience), 5 (Flexibility), 6
(Understanding), 7 (Recommend to others) and 8 (Wish to
continue). Items 2 (Perceived hyperglycemia frequency) and 3
(Perceived hypoglycemia frequency) were treated as separate
variables. The quality of life instrument was not designed to
measure treatment satisfaction related to the device.
Adverse experiences were monitored throughout the study,
and were rated by investigators for intensity and relationship to
the study drug. Adverse experiences with an onset date of up
to 2 weeks after concluding treatment were assessed in person.
Statistical Analysis
Two analyses were carried out. In the intention-to-treat analysis
(Table S1), measures that were missing for participants who
discontinued the study were replaced with baseline measures.
In the second analysis, only data from participants who com-
pleted the study (through the 12-week follow-up period) were
included. We carried out a completed case analysis rather than
an intention-to-treat analysis, because there were few dropouts,
and their reasons for dropping out were unrelated to baseline
values or responses.
The data are expressed as means – standard deviation, unless
otherwise indicated. The Statistical Package for the Social
Sciences (version 11.0; SPSS, Inc., Chicago, IL, USA) was used
for the statistical analyses. For univariate analyses between the
patient groups, Student’s t-test or the Mann–Whitney U-test was
used, as appropriate. Values of P < 0.05 showed signiﬁcance.
RESULTS
Baseline Metabolic Parameters
Patients were recruited between January 2011 and February
2012, with follow up continuing for 12 weeks thereafter. A total
of 122 patients who consented to participate in the study were
screened (Figure 1). The mean age of the patients was
64.7 – 12.4 years, and mean BMI was 24.7 – 5.2 kg/m2. FPG,
HbA1c, and CPR levels were 166.6 – 49.2 mg/dL, 8.0 – 1.5%
and 1.8 – 1.1 ng/mL, respectively. The patients were random-
ized into two treatment groups (a liraglutide group and a vil-
dagliptin group), which were generally well balanced with
respect to baseline demographics and disease characteristics. Of
the 122 patients enrolled in the study, ﬁve dropped out after
randomization and before the intervention (Figure 1). All of
the patients analyzed were ﬁnally administered with 0.9 mg of
liraglutide, and took more than 80% compliance of study medi-
cation. A total of 53 of 58 patients assigned to vildagliptin, and
49 of 54 assigned to liraglutide achieved 100% compliance of
the study medication in the present study.
Clinical Outcomes
Compared with baseline values, FPG and HbA1c levels were
signiﬁcantly decreased in both groups at the end of the study
(Table 1). Both liraglutide and vildagliptin signiﬁcantly lowered
HbA1c within 12 weeks after switching from sitagliptin, but the
decrease in HbA1c was greater in the liraglutide group than in
the vildagliptin group (-0.67 – 0.12% vs -0.36 – 0.53%). Lira-
glutide signiﬁcantly lowered the BMI from 25.4 – 4.8 to
24.3 – 5.8 kg/m2 (P = 0.018), whereas vildagliptin did not
affect the BMI. Both liraglutide and vildagliptin signiﬁcantly
lowered FPG within 12 weeks after switching from sitagliptin.
Vildagliptin lowered the IRI (from 6.9 – 7.4 to 4.9 – 3.6 IU/L,
P = 0.044) and CPR (from 1.9 – 1.2 to 1.5 – 0.7 ng/mL,
P = 0.024), whereas liraglutide did not affect either factor. Vil-
dagliptin increased the serum level of adiponectin from
3.6 – 2.5 to 4.1 – 2.7 (P = 0.000); liraglutide had no effect on
serum adiponectin levels. Vildagliptin, but not liraglutide, signif-
icantly decreased HOMA-IR and increased QUICKI (Table 1).
However, as shown in Table S2, vildagliptin-mediated change
in HbA1c did not correlate with both basal and changes in
HOMA-IR and QUICKI, whereas vildagliptin signiﬁcantly
decreased HOMA-IR and increased QUICKI. Liraglutide signif-
icantly increased CPI and HOMA-b, whereas vildagliptin did
not affect CPI or HOMA-b. At the end of the study, systolic
blood pressure, blood urea nitrogen, AST, ALT, cGTP, ALP,
TG, HDL-C, U-Alb, U-8OHdG, TNF-a and leptin levels were
not changed signiﬁcantly in either group.
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Changes in Serum Fatty Acid Concentrations
Vildagliptin signiﬁcantly decreased the arachidic acid level and
signiﬁcantly increased the docosahexaenoic acid (DHA),
whereas liraglutide did not affect either factor. Conversely,
liraglutide signiﬁcantly decreased the eicosatrienoic acid level,
whereas vildagliptin did not affect it. The levels of arachidonic
acid and eicosapentaenoic acid (EPA) were signiﬁcantly
increased in the vildagliptin group compared with the liraglu-
tide group (Table 2).
Treatment Satisfaction
The mean DTSQ scores for the vildagliptin and liraglutide
groups were 25.5 – 6.3 and 25.1 – 4.7, respectively, at baseline
and 25.8 – 5.6 and 24.4 – 7.3, respectively, at the end of the
study. The DTSQ scores were not signiﬁcantly affected by
either agent after switching from sitagliptin. In addition, there
were no signiﬁcant differences between the two treatment
groups in terms of the changes in treatment satisfaction score
(the sum of items 1, 4, 5, 6, 7 and 8), perceived frequency of
hyperglycemia (item 2), or hypoglycemia (item 3) at the end of
the study (Table 3).
Adverse Events
The most common adverse events were gastrointestinal
symptoms, which occurred with similar frequencies in both
treatment groups (Table 4). The distribution of most other
adverse events was similar between treatment groups. Nausea
occurred in one patient treated with liraglutide. No pancreatitis
or hypoglycemia occurred in present study. In the vildagliptin
group, one woman reported hair loss. One episode of liver
injury, which the investigator regarded as acute and likely to be
related to the study drug, was diagnosed after 12 weeks of
vildagliptin therapy in a 64-year-old woman. The investigator
discontinued vildagliptin, and switched to liraglutide according
to the study protocol. After 3 months of the discontinuation,
the patient’s liver enzymes recovered to the normal range. In
the liraglutide group, one woman suffered a fracture of the
shaft of the femur.
DISCUSSION
This is the ﬁrst report from an open-label, randomized, paral-
lel-group study to compare the effects of daily doses of 100 mg
vildagliptin and 0.9 mg liraglutide on glycemic control and
bodyweight in people with type 2 diabetes who did not achieve
adequate glycemic control with sitagliptin-based regimens. We
showed that after switching from sitagliptin, both vildagliptin
and liraglutide signiﬁcantly lowered HbA1c and that liraglutide
was superior to vildagliptin in lowering HbA1c. Vildagliptin
100 mg ameliorated FPG and HbA1c 12 weeks after switching
from sitagliptin 50 mg.
Assessed for eligibility (n = 131)
Excluded (n = 9)
Not meeting inclusion criteria (n = 4)
Declined to participate (n = 5)
Randomized (n = 122)
Allocated to the vildagliptin group (n = 62) Allocated to the liraglutide group (n = 60)
Received allocated intervention (n = 57)
Did not received allocated intervention (n = 3)
Lost to follow-up (n = 0)
Discontinued intervention (n = 1)
Analyzed (n = 54)
Excluded from analyzed (n = 2)
Withdraw participation (4W~)
Received allocated intervention (n = 60)
Did not receive allocated intervention (n = 2)
Lost to follow-up (n = 0)
Analyzed (n = 58)
Excluded from analyzed (n = 1)
Discontinued intervention (n = 1)
Withdraw participation (8w~)
Figure 1 | Flow diagram.
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Liraglutide signiﬁcantly decreased bodyweight, as expected,
whereas vildagliptin did not affect bodyweight. Although
DPP-4 inhibitors increase active GLP-1 concentrations two- or
threefold compared with baseline14, the stimulation of GLP-1
receptor activity by liraglutide is estimated to be several times
that resulting from DPP-4 inhibition15. In the present study,
liraglutide lowered HbA1c independently of weight loss (Table
S2). This ﬁnding is supported by a recent meta-analysis that
included the Liraglutide Effect and Action in Diabetes trials16.
Liraglutide signiﬁcantly increased CPI and HOMA-b,
whereas vildagliptin signiﬁcantly decreased IRI and CPI. The
present ﬁnding that liraglutide decreased bodyweight and
fasting plasma glucose, and increased markers for b-cell func-
tion, such as HOMA-b and CPI, is in agreement with the pre-
vious reports5,17. Interestingly, DPP-4 inhibitor vildagliptin did
not affect the marker for b-cell function, but increased insulin
sensitivity marker QUICKI. The most acceptable interpretation
of this ﬁnding could be that GLP-1 receptor agonists improve
b-cell function5,17, whereas vildagliptin improves insulin sensi-
tivity. In addition, differences in the mode of action between
GLP-1 analogs and DPP-4 inhibitors, which might stem from a
difference in the dynamics of GLP-1 action or different effects
on glucagon secretion, gastric empting and the autonomic
nervous system, could also be involved in this phenomenon.
Table 1 | Changes in the characteristics of patients between baseline and 12 weeks
Vildagliptin P* Liraglutide P* P**
Before After Before After
Male:female 36:22 35:19




Bodyweight (kg) 63.2 – 14.1 63.3 – 13.9 0.694 65.8 – 16.1 64.2 – 16.2 0.000 0.000
Body mass index (kg/m2) 24.5 – 4.6 24.2 – 5.4 0.435 25.4 – 4.8 24.3 – 5.8 0.018 0.000
Waist circumference (cm) 90.0 – 10.7 89.3 – 10.4 0.061 91.1 – 11.6 89.6 – 12.0 0.006 0.229
Systolic blood pressure (mmHg) 130.3 – 24.7 122.4 – 29.1 0.055 133.3 – 19.1 130.8 – 26.5 0.448 0.360
Fasting plasma glucose (mg/dL) 169.5 – 42.5 155.2 – 45.8 0.010 161.4 – 52.2 144.2 – 45.0 0.016 0.736
HbA1c (%) 8.1 – 1.2 7.8 – 1.1 0.000 8.0 – 0.9 7.3 – 1.0 0.004 0.026
1,5-Anhydroglucitol (mg/mL) 6.5 – 5.3 6.9 – 5.1 0.394 7.4 – 5.6 10.7 – 6.8 0.000 0.001
BUN (mg/dL) 15.9 – 5.5 15.0 – 4.9 0.117 15.6 – 6.0 14.6 – 5.6 0.280 0.739
Cre (mg/dL) 0.70 – 0.22 0.67 – 0.22 0.018 0.74 – 0.22 0.75 – 0.24 0.954 0.114
Serum aspartate aminotransferase (IU/L) 27.8 – 17.7 33.6 – 52.8 0.380 26.6 – 14.9 30.5 – 29.5 0.133 0.863
Serum alanine aminotransferase (IU/L) 30.2 – 20.9 32.7 – 35.4 0.579 30.1 – 20.9 36.2 – 39.6 0.141 0.557
Plasma gamma-glutamyltransferase (IU/L) 37.0 – 29.5 37.1 – 37.0 0.983 43.0 – 49.4 50.4 – 72.8 0.388 0.454
Alkaline phosphatase (IU/L) 226.6 – 83.1 230.5 – 92.8 0.132 213.5 – 66.8 219.0 – 11.9 0.570 0.499
Total cholesterol (mg/dL) 185.1 – 32.8 183.8 – 33.0 0.710 180.1 – 34.0 168.9 – 41.5 0.007 0.117
Triglycerides (mg/dL) 138.8 – 101.5 125.6 – 72.5 0.242 125.0 – 80.6 114.8 – 62.7 0.184 0.824
HDLC (mg/dL) 52.9 – 17.0 52.5 – 17.3 0.522 52.9 – 14.1 53.0 – 13.6 0.936 0.661
sdLDL-C (mg/dL) 36.2 – 17.0 37.1 – 15.9 0.568 35.1 – 14.1 31.8 – 13.4 0.021 0.042
Fasting serum insulin (IU/L) 6.9 – 7.4 4.9 – 3.6 0.044 6.0 – 5.2 7.9 – 10.3 0.162 0.020
CPR (ng/mL) 1.9 – 1.2 1.5 – 0.7 0.024 1.7 – 0.9 1.9 – 1.1 0.087 0.004
U-Alb (mg/gCre) 157.8 – 514.1 117.4 – 280.2 0.518 91.0 – 173.4 160.8 – 540.3 0.244 0.202
U-8OHdG (ng/mgCre) 11.5 – 4.0 11.9 – 4.0 0.449 11.5 – 4.6 11.3 – 5.9 0.657 0.681
Adiponectin (lg/mL) 3.6 – 2.5 4.1 – 2.7 0.000 3.8 – 2.4 4.0 – 2.4 0.210 0.859
TNF-a (pg/mL) 1.5 – 1.0 1.6 – 0.9 0.752 1.2 – 0.5 1.3 – 0.4 0.602 0.319
Leptin (ng/mL) 8.1 – 6.9 8.1 – 6.4 0.954 6.9 – 5.7 7.2 – 6.8 0.580 0.546
QUICKI 0.35 – 0.05 0.36 – 0.04 0.020 0.36 – 0.05 0.36 – 0.06 0.835 0.100
HOMA-IR 3.1 – 4.0 1.9 – 1.5 0.038 2.5 – 2.7 2.9 – 4.4 0.503 0.056
CPI 1.1 – 0.6 1.1 – 0.6 0.286 1.1 – 0.6 1.4 – 0.8 0.003 0.002
HOMA-b 25.5 – 21.9 24.6 – 22.5 0.724 25.5 – 19.5 39.4 – 49.8 0.029 0.029
Data are expressed as mean – standard deviation. *P-value for the intragroup comparison (baseline vs 12 weeks); **P-value for the intergroup
comparison (difference in changes from baseline between groups). BUN, blood urea nitrogen; CPI, C-peptide immunoreactivity index; CPR, C-pep-
tide immunoreactivity; Cre, creatinine; HDLC, high-density lipoprotein cholesterol; HOMA-b, homeostasis model assessment-b; HOMA-IR, homeostasis
model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index; sdLDL, small dense low-density lipoprotein; TNF, tumor
necrosis factor; U-8OHdG, urinary 8-hydroxy-deoxyguanosine; U-Alb, urinary albumin (measured by immunoturbidimetry and adjusted using urinary
creatinine).
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The greater reductions in HbA1c and bodyweight with
liraglutide vs vildagliptin were probably as a result of the phar-
macological stimulation of GLP-1 receptor activity with
liraglutide, whereas physiological concentrations of endogenous
GLP-1 are achieved with vildagliptin. Nevertheless, both liraglu-
tide- and vildagliptin-mediated improvements in glycemic con-
trol did not correlate with indices for insulin secretion and
insulin sensitivity (Table S2), suggesting that unique and as yet
unrecognized mechanisms might underlie the actions of each
agent.
Liraglutide lowered total cholesterol and sdLDL in the pres-
ent study, unlike in previous studies17,18. Vildagliptin did not
affect either measure. In general, GLP-1 receptor agonists
appear to beneﬁcially inﬂuence fasting lipid parameters,
although the effects are small, with reductions vs control of up
to 14% for total cholesterol19. For DPP-4 inhibitors, the results
Table 2 | Changes in plasma fatty acid composition between baseline and 12 weeks in patients who completed the study
Vildagliptin P* Liraglutide P* P**
Before After Before After
C12:0 (lauric acid) 2.3 – 2.5 2.5 – 3.2 0.762 1.8 – 0.9 1.9 – 1.2 0.759 0.855
C14:0 (myristic acid) 26.8 – 16.4 27.1 – 13.8 0.941 26.1 – 12.0 25.0 – 14.4 0.696 0.752
C16:0 (palmitic acid) 683.9 – 148.5 693.2 – 167.8 0.781 659.6 – 190.5 637.8 – 198.0 0.507 0.505
C16:1n-7 (palmitoleic acid) 66.3 – 35.4 74.0 – 32.8 0.122 63.2 – 29.8 61.9 – 32.0 0.780 0.177
C18:0 (stearic acid) 191.5 – 32.0 187.2 – 35.8 0.563 187.5 – 32.8 197.1 – 39.2 0.307 0.701
C18:1n-9 (oleic acid) 599.1 – 158.7 618.7 – 164.3 0.566 582.6 – 181.3 564.5 – 196.4 0.647 0.468
C18:2n-6 (linoleic acid) 736.0 – 168.4 724.4 – 197.3 0.683 751.8 – 141.8 732.0 – 166.9 0.560 0.851
C18:3n-6 (c-linolenic acid) 9.4 – 4.3 8.9 – 3.8 0.523 7.6 – 3.9 7.8 – 4.2 0.721 0.465
C18:3n-3 (a-linolenic acid) 23.5 – 9.7 24.2 – 10.5 0.755 24.5 – 10.1 25.8 – 13.9 0.707 0.880
C20:0n-6 (arachidic acid) 7.1 – 1.3 6.7 – 1.4 0.043 6.4 – 1.5 6.4 – 1.5 0.977 0.129
C20:1n9 (eicosenoic acid) 4.9 – 1.2 5.3 – 1.6 0.213 4.8 – 0.9 5.0 – 1.6 0.483 0.622
C20:2n6 (eicosadienoic acid) 5.5 – 1.2 5.6 – 1.1 0.652 5.8 – 1.2 5.7 – 1.9 0.732 0.576
C20:3n9 (eicosatrienoic acid) 1.8 – 1.2 2.0 – 1.1 0.300 1.6 – 0.6 1.3 – 0.5 0.011 0.030
C20:3n-6 (Dihomo-c-linolenic acid) 34.1 – 12.1 32.1 – 8.7 0.272 36.8 – 14.9 33.6 – 13.9 0.250 0.702
C20:4n-6 (arachidonic acid) 175.0 – 36.9 193.2 – 37.9 0.009 164.2 – 40.5 164.0 – 37.6 0.983 0.046
C20:5n-3 (eicosapentaenoic acid) 82.3 – 38.1 99.5 – 58.2 0.021 73.4 – 30.5 70.7 – 32.2 0.666 0.037
C22:0 (behenic acid) 18.0 – 3.4 17.3 – 4.2 0.223 17.6 – 3.8 16.4 – 4.0 0.055 0.559
C22:1n-9 (erucic acid) 1.5 – 0.4 1.4 – 0.5 0.327 1.7 – 0.7 1.4 – 0.4 0.056 0.288
C22:4n-6 (docosatetraenoic acid) 4.0 – 1.7 4.3 – 1.4 0.373 3.7 – 1.2 3.4 – 1.1 0.319 0.182
C22:5n-3 (docosapentaenoic acid) 23.7 – 8.0 26.8 – 12.6 0.065 21.8 – 7.3 20.8 – 7.8 0.342 0.037
C22:6n-3 (docosahexaenoic acid) 164.5 – 49.6 186.4 – 64.6 0.013 147.6 – 38.3 151.7 – 45.2 0.578 0.108
C24:1 (nervonic acid) 34.3 – 6.9 34.1 – 6.9 0.849 32.6 – 8.6 32.3 – 8.1 0.727 0.922
Data are expressed as mean – standard deviation. *P-value for the intragroup comparison (baseline vs 12 weeks); **P-value for the intergroup
comparison (difference in changes from baseline between groups).
Table 3 | Diabetes treatment satisfaction questionnaire scores at baseline and 12 weeks in patients who completed the study
Vildagliptin P* Liraglutide P* P**
Before After Before After
Q1 4.1 – 1.4 3.9 – 1.4 0.424 4.0 – 0.7 4.0 – 1.3 0.873 0.628
Q2 3.1 – 1.7 2.8 – 2.0 0.503 3.6 – 1.7 3.3 – 0.3 0.312 0.958
Q3 1.6 – 1.6 1.2 – 1.6 0.437 1.4 – 1.6 1.5 – 1.6 0.747 0.400
Q4 4.3 – 1.6 4.8 – 1.0 0.117 4.3 – 1.4 4.3 – 1.3 0.759 0.300
Q5 4.2 – 1.6 4.5 – 1.2 0.348 4.2 – 1.0 4.0 – 1.4 0.527 0.264
Q6 4.0 – 1.4 4.3 – 0.9 0.296 4.3 – 0.9 3.9 – 1.4 0.236 0.113
Q7 3.9 – 1.5 4.2 – 1.2 0.492 4.2 – 1.1 4.1 – 1.4 0.780 0.473
Q8 4.0 – 1.5 4.2 – 1.3 0.700 4.2 – 1.0 4.0 – 1.4 0.548 0.495
SUM 25.5 – 6.3 25.8 – 5.6 0.794 25.1 – 4.7 24.4 – 7.3 0.579 0.595
Data are expressed as mean – standard deviation. *P-value for the intragroup comparison (baseline vs 12 weeks); **P-value for the intergroup
comparison (difference in changes from baseline between groups).
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are diverse and inconclusive19. Incretin-based therapies might
particularly affect postprandial lipid proﬁles and reduce fasting
lipid levels. Switching from sitagliptin to vildagliptin signiﬁ-
cantly increased the serum adiponectin level in the present
study. However, a previous clinical study concluded that neither
sitagliptin nor vildagliptin affected adiponectin levels20. The
present ﬁndings support a previous report that serum levels of
DPP-4 negatively correlate with adiponectin levels21, and sug-
gest that vildagliptin is superior to sitagliptin in increasing
adiponectin levels. Vildagliptin also signiﬁcantly improved cre-
atinine levels in the present study. Vildagliptin is well tolerated,
with a good safety proﬁle in patients with type 2 diabetes and
moderate or severe renal impairment22, as the excretion of
unmodiﬁed vildagliptin by the kidneys is <25%23. There were
no signiﬁcant differences between the two treatment groups in
terms of changes in liver transaminases in the present study. It
could be relevant that our patients showed only mild elevation
of transaminase levels at baseline, given that GLP-1 receptor
agonists were associated with signiﬁcant improvements in
abnormal liver transaminases, biomarkers of hepatocytes, and
hepatic steatosis in patients with non-alcoholic fatty liver
disease in two human reports24,25.
The present study is the ﬁrst to show vildagliptin-mediated
changes in serum fatty acid proﬁles in human or animals.
Vildagliptin, but not liraglutide, elevated serum concentrations
of EPA and DHA after 3 months of administration. The effects
of vildagliptin on fatty acid proﬁles were independent of its
effects on glycemic control (Table S2), insulin sensitivity, and
cardiovascular markers. The molecular mechanisms underlying
the vildagliptin-mediated effects on fatty acid levels and insulin
secretion should be pursued in future studies. In contrast to a
previous report26, baseline levels of DHA, but not EPA,
predicted the vildagliptin-mediated improvement in glycemic
control (Table S2). This ﬁnding might be relevant to the
observation that GLP-1 secretion was induced by x-3
polyunsaturated fatty acid (PUFA) administration in basic stud-
ies27,28. In addition, G protein-coupled receptor (GPR) 120
functions as a receptor for unstructured long-chain fatty acids,
and stimulation of GPR 120 with DHA promotes GLP-1 secre-
tion in vitro27. Furthermore, intracolonic administration of
DHA stimulates GLP-1 secretion in vivo28.
Quality of life, assessed using the DTSQ, was not impaired
in either group after switching from sitagliptin, despite the fact
that liraglutide was given by injection and vildagliptin should
be taken twice a day. In addition, the change in quality of life
did not differ signiﬁcantly between the two treatment groups.
This result is surprising, because it suggests that switching from
a once-daily oral agent to either an injected agent or a twice-
daily oral agent did not worsen the patients’ quality of life. We
speculate that increased treatment satisfaction was associated
with improved clinical outcomes in the present study, as
suggested previously29.
Overall, both liraglutide and vildagliptin were well tolerated.
Most of the adverse experiences were mild, and no serious
adverse events, such as pancreatitis, which was reported in the
liraglutide LEAD studies17,30–32, occurred in the present study.
In summary, vildagliptin-mediated improvements in glycemic
control did not correlate with indices for insulin secretion and
insulin sensitivity. Switching from sitagliptin to liraglutide is
useful in managing hyperglycemia and weight. Each agent
exerts unique pleiotropic effects on lipid proﬁle, adiponectin
level and fatty acid composition.
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Table 4 | Adverse experiences of patients who completed the study
Vildagliptin Liraglutide
Appetite loss 1 3
Skin itching 3 0
Constipation 2 1
Diarrhea 2 1
Chest discomfort 2 0
Heartburn 1 1
Feeling of fullness in the abdomen 0 1
Nausea 0 1
Injection site redness 0 1
Influenza infection 1 0
Fracture of shaft of femur 0 1
Dizziness 0 1
Liver injury 1 0
Loss of hair 1 0
Data are number of participants.
198 J Diabetes Invest Vol. 6 No. 2 March 2015 ª 2014 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd
C L I N I C A L T R I A L
Takeshita et al. http://onlinelibrary.wiley.com/journal/jdi
REFERENCES
1. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive
control of glucose on cardiovascular outcomes and death
in patients with diabetes mellitus: a meta-analysis of
randomised controlled trials. Lancet 2009; 373: 1765–1772.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like
peptide-1 receptor agonists and dipeptidyl peptidase-4
inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–1705.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
hyperglycemia in type 2 diabetes: a patient-centered
approach: position statement of the American Diabetes
Association (ADA) and the European Association for the
Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–
1379.
4. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus
sitagliptin for patients with type 2 diabetes who did not
have adequate glycaemic control with metformin: a 26-
week, randomised, parallel-group, open-label trial. Lancet
2010; 375: 1447–1456.
5. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl
peptidase-4 inhibitors and HbA1c target of <7% in type 2
diabetes: meta-analysis of randomized controlled trials.
Diabetes Obes Metab 2011; 13: 594–603.
6. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor
agonists and DPP-4 inhibitors: meta-analysis and systematic
review. Clin Ther 2012; 34: 1247–1258.
7. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar
glycaemic control as glimepiride (both in combination with
metformin) and reduces body weight and systolic blood
pressure in Asian population with type 2 diabetes from
China, South Korea and India: a 16-week, randomized,
double-blind, active control trial. Diabetes Obes Metab 2011;
13: 81–88.
8. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A.
Diagnostic criteria for diabetes mellitus and other categories
of glucose intolerance: 1997 criteria by the Expert
Committee on the Diagnosis and Classification of Diabetes
Mellitus (ADA), 1998 WHO consultation criteria, and 1985
WHO criteria. World Health Organization. Diabetes Res Clin
Pract 1999; 44: 21–26.
9. Katz A, Nambi SS, Mather K, et al. Quantitative insulin
sensitivity check index: a simple, accurate method for
assessing insulin sensitivity in humans. J Clin Endocrinol
Metab 2000; 85: 2402–2410.
10. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis
model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in
man. Diabetologia 1985; 28: 412–419.
11. Bradley C. The diabetes treatment satisfaction questionnaire.
In: Bradley C (ed). Handbook of Psychology and Diabetes: A
Guide to Psychological Measurement in Diabetes Research
and Practice. Harwood Academic Publishers, Chur, 1994;
111–132.
12. Bradley C, Gamsu DS. Guidelines for encouraging
psychological well-being: report of a Working Group of the
World Health Organization Regional Office for Europe and
International Diabetes Federation European Region St
Vincent Declaration Action Programme for Diabetes. Diabet
Med 1994; 11: 510–516.
13. Ishii H, Bradley C, Riazi A, et al. The Japanese version of the
Diabetes Treatment Satisfaction Questionnaire (DTSQ):
translation and clinical evaluation. Journal of Clinical and
Experimental Medicine 2000; 192: 809–814.
14. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the
dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy
on glycemic control in patients with type 2 diabetes.
Diabetes Care 2006; 29: 2632–2637.
15. Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with
the long-acting glucagon-like peptide 1 derivative
liraglutide (NN2211) markedly improves 24-h glycemia and
alpha- and beta-cell function and reduces endogenous
glucose release in patients with type 2 diabetes. Diabetes
2004; 53: 1187–1194.
16. Schmidt WE, Gough S, Madsbad NS, et al. Liraglutide, a
human GLP-1 analogue, lowers HbA1c independent of
weight loss. Diabetologia 2009; 52(Suppl. 1): S289.
17. Buse J, Rosenstock J, Sesti G et al. Liraglutide once a day
versus exenatide twice a day for type 2 diabetes: a 26-week
randomised, parallel-group, multinational, open-label trial
(LEAD-6). Lancet 2009; 374: 39–47.
18. Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved
glycaemia correlates with liver fat reduction in obese, type
2 diabetes, patients given glucagon-like peptide-1 (GLP-1)
receptor agonists. PLoS One 2012; 7: e50117.
19. van Genugten RE, M€oller-Goede DL, van Raalte DH, et al.
Extra-pancreatic effects of incretin-based therapies: potential
benefit for cardiovascular-risk management in type 2
diabetes. Diabetes Obes Metab 2013; 15: 593–606.
20. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of
oxidative stress and inflammation by blunting daily acute
glucose fluctuations in patients with type 2 diabetes: role of
dipeptidyl peptidase-IV inhibition. Diabetes Care 2012; 35:
2076–2082.
21. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl
peptidase 4 is a novel adipokine potentially linking obesity
to the metabolic syndrome. Diabetes 2011; 60: 1917–1925.
22. Kothny W, Shao Q, Groop PH, et al. One-year safety,
tolerability and efficacy of vildagliptin in patients with type
2 diabetes and moderate or severe renal impairment.
Diabetes Obes Metab 2012; 14: 1032–1039.
23. He H, Tran P, Yin H, et al. Absorption, metabolism, and
excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4
inhibitor, in humans. Drug Metab Dispos 2009; 37: 536–544.
24. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of
two years of exenatide treatment on diabetes, obesity, and
hepatic biomarkers in patients with type 2 diabetes: an
ª 2014 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Invest Vol. 6 No. 2 March 2015 199
C L I N I C A L T R I A L
http://onlinelibrary.wiley.com/journal/jdi Vildagliptin vs liraglutide
interim analysis of data from the open-label, uncontrolled
extension of three double-blind, placebo-controlled trials.
Clin Ther 2007; 29: 139–153.
25. Tushuizen ME, Bunck MC, Pouwels PJ, et al. Incretin
mimetics as a novel therapeutic option for hepatic
steatosis. Liver Int 2006; 26: 1015–1017.
26. Senmaru T, Fukui M, Kobayashi K, et al. DPP-IV inhibitors is
effective in patients with type 2 diabetes with high serum
eicosapentaenoic acid concentrations. J Diabetes Invest
2012; 3: 498–502.
27. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids
regulate gut incretin glucagon-like peptide-1 secretion
through GPR120. Nat Med 2005; 11: 90–94.
28. Morishita M, Tanaka T, Shida T, et al. Usefulness of colon
targeted DHA and EPA as novel diabetes medications that
promote intrinsic GLP-1 secretion. J Control Release 2008;
132: 99–104.
29. Peyrot M, Rubin RR. How does treatment satisfaction work?
Diabetes Care 2009; 32: 1411–1417.
30. Garber A, Henry R, Ratner R et al. Liraglutide versus
glimepiride monotherapy for type 2 diabetes (LEAD-3
Mono): a randomised, 52-week, phase III, double-blind,
parallel-treatment trial. Lancet 2009; 373: 473–481.
31. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily
human GLP-1 analogue, added to a sulphonylurea over
26 weeks produces greater improvements in glycaemic
and weight control compared with adding rosiglitazone or
placebo in subjects with type 2 diabetes (LEAD-1 SU).
Diabet Med 2009; 26: 268–278.
32. Nauck M, Frid A, Hermansen K et al. Efficacy and safety
comparison of liraglutide, glimepiride, and placebo, all in
combination with metformin, in type 2 diabetes: the LEAD
(liraglutide effect and action in diabetes)-2 study. Diabetes
Care 2009; 32: 84–90.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Table S1 | Changes in the characteristics of patients between baseline and 12 weeks (intention to treat analysis).
Table S2 | Factors associated with a change in glycated hemoglobin.
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